Tarsus Pharmaceuticals (TARS) Expected to Announce Earnings on Thursday

Key Points

• Tarsus is set to report Q1 2026 results before the market opens on May 7, with analysts projecting EPS of ($0.25) and revenue of $153.116 million; an earnings call is scheduled for May 6 at 4:30 PM ET.
• The company last missed EPS on Feb. 23 (reported ($0.20) vs. a ($0.19) estimate) but grew revenue to $151.67M; analysts expect full-year EPS of -$1 and next-year EPS of $3, with a consensus rating of Moderate Buy and a $90.67 target.
• TARS trades with a market cap of about $2.58 billion and a negative P/E, and insiders sold ~79,391 shares (~$5.43M) over the last three months while institutional ownership is roughly 90%.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.25) per share and revenue of $153.1160 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The company had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. On average, analysts expect Tarsus Pharmaceuticals to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Tarsus Pharmaceuticals Trading Down 2.3%

TARS opened at $60.67 on Thursday. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -37.45 and a beta of 0.63. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The business has a fifty day moving average price of $69.10 and a 200 day moving average price of $72.11.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the sale, the general counsel directly owned 63,959 shares of the company's stock, valued at $4,285,253. The trade was a 6.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dianne C. Whitfield sold 4,174 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the sale, the insider directly owned 35,028 shares of the company's stock, valued at $2,346,876. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 79,391 shares of company stock worth $5,432,035 over the last three months. Company insiders own 8.97% of the company's stock.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Occudo Quantitative Strategies LP lifted its holdings in Tarsus Pharmaceuticals by 127.7% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 11,905 shares of the company's stock worth $482,000 after buying an additional 6,677 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Tarsus Pharmaceuticals by 31.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,591 shares of the company's stock worth $451,000 after buying an additional 1,836 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at about $402,000. Public Employees Retirement Association of Colorado purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $367,000. Finally, Quarry LP lifted its holdings in shares of Tarsus Pharmaceuticals by 103.3% in the 3rd quarter. Quarry LP now owns 6,100 shares of the company's stock valued at $363,000 after purchasing an additional 3,100 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TARS has been the subject of several analyst reports. The Goldman Sachs Group reissued a "neutral" rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Lifesci Capital raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, March 16th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an "outperform" rating and a $98.00 target price for the company. Zacks Research cut Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $90.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.